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Abstract
Background: MET is a proto-oncogene with its copy number (CN) alterations been reported in some cancers, but
not in primary intestinal diffuse large B-cell lymphoma (PI-DLBL) yet.
Methods: In this retrospective study, we performed histology and chart reviews, immunohistochemistry and
quantitative polymerase chain reaction for MET CN alterations on 28 surgically resected PI-DLBLs.
Results: There were 12 men and 16 women with a median age of 70 and a mean follow-up of 32 months. The
median MET CN was 2.20 (range, 1.04 to 3.35). CN gain was observed in 11 cases, including 5 with CN greater than
3. Nine patients (32%) had diploid CN and eight (29%) with CN loss. Patients with gain or diploid CN showed
significantly worse prognosis (P = 0.046) than those with CN loss. Furthermore, MET CN greater than 3 was
associated with an adverse outcome (P = 0.003). Intestinal perforation at presentation was the sole
clinicopathological factor associated with a poor prognosis (P = 0.004) and perforation was correlated with CN
greater than 3 (P = 0.002).
Conclusions: Our finding of MET CN gain as a poor prognostic factor in PI-DLBL patients might serve as the
rationale for targeting MET signaling pathway in the treatment of these patients.
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Background
Copy number alterations (CNAs) of genes are indica-
tions of genomic instability that are common in cancers
and have been known to be associated with the develop-
ment of malignancy [1,2]. CNAs of specific genes may
deregulate signal pathways that enhance the proliferation
and inhibit the apoptosis of tumor cells. Cumulative evi-
dences suggest a link between CNAs and prognosis of
cancer patients [3]. CNAs of particular genes may pro-
vide insights into the pathogenesis of certain neoplasms
and the clues for target therapy. Hepatocyte growth fac-
tor (HGF)/MET pathway is one of the most commonly
activated signaling pathways in human malignancies.
Deregulated HGF/MET signaling axis contributes to
tumorigenesis and invasion/metastasis by the following
cellular behaviors collectively described as invasive
growth: proliferation and survival (resistance to apop-
totic signals), increased cell motility, cell dissociation
(scattering), epithelial tubulogenesis, infiltration of tis-
sues, and stimulation of angiogenesis [4-6]. The HGF/
MET pathway may be activated by mutations or gen-
omic amplification of the MET gene and ligand-
independent kinase activation by extracellular proteins,
autocrine overexpression of HGF ligand, and increased
expression of HGF activator [6,7]. Recent studies have
provided important evidence for MET CNAs in gastric
cancer and non-small cell lung cancer (NSCLC) [8-10].
Although some studies have shown that HGF/MET
pathway might be implicated in B-cell neoplasms par-
ticularly diffuse large B-cell lymphoma (DLBL) and mul-
tiple myeloma (MM) [11-18], it is still an unresolved* Correspondence: cmh5301@mail.chimei.org.tw2Department of Pathology, Chi-Mei Medical Center, Tainan, Taipei Medical
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issue for the impact of MET CNA in the survival of
patients with these hematological malignancies.
In a previous study, we identified perforation as the
sole clinicopathological prognostic factor in patients
with primary intestinal DLBL (PI-DLBL) [19]. In this
current retrospective study we investigated the prognos-
tic impact of MET CNAs by quantitative polymerase
chain reaction (qPCR) method and found that in
addition to perforation, MET CNAs were also signifi-
cantly associated with prognosis.
Materials and methods
Case selections and clinical data
Strict inclusion and diagnostic criteria for PI-DLBL were
applied as previously reported [19]. Medical records
were reviewed and overall survival was measured from
the date of diagnosis to the date of last follow-up. Chi-Mei
Institutional Review Board approved this study.
DNA extraction
To avoid the contamination by normal cells, we
reviewed the HE sections of each case and chose those
containing greater than 90% tumor cells without or with
only minimal tumor necrosis for DNA extraction. Three
to five 10 μm thick paraffin sections of each case were
cut into an eppendorf tube from a representative block
with disposable blades. The paraffin rolls were de-
paraffinized with xylene followed by three washings
with ethanol. Paraffin-free tissue was dried in a heating
box for 15 min at 37°C and then subjected to the DNA
extraction procedures using QIAamp DNA mini kit
(Qiagen, Hilden, Germany). The quality and DNA con-
centration were measured by NanoPhotometer (IMPLEN,
München, Germany). DNA with 260/280 ratios of 1.6–2.0
with a minimal concentration of 25 ng/μl DNA were
required for qPCR assay.
Copy number assay
We performed qPCR assay to determine the CNAs of
MET gene by using the commercially available 6-
carboxy-fluorescine (FAM)-labeled MET probe (Applied
Biosystems assay ID no. Hs02764674, Applied Biosys-
tems, Foster City, CA). Ribonuclease P (RNase P), which
is known to exist in two copies, was used as the endogen-
ous control with 4,7,2-trichloro-7-phenyl-6-carboxyfluor-
escein (VIC)-labeled probe (Applied Biosystems Part no.
4403326). The peripheral blood mononuclear cells from
six healthy individuals served as control samples. Each ex-
periment was performed using a 96-well optical PCR plate
and the StepOnePlus real-time PCR machine (Applied
Biosystems) with default cycling conditions. According to
manufacturer’s instruction, a total of 10 ng of genomic
DNA was added to the PCR reaction mixture containing
1× final concentration TaqMan Gene Expression PCR
Master Mix (Applied Biosystems) and 1x final pre-
designed primer/probe Mix (Applied Biosystems) in a
final volume of 10μL. Each sample was run in triplicate.
After amplification, the Ct values for both target and refer-
ence genes were imported into the CopyCaller Software
(Applied Biosystems) for data analysis. The CN of the tar-
get gene was determined by comparative quantitative
threshold cycle (ΔΔCt) method where ΔΔCt = (Ct of tar-
get gene, test sample − Ct of RNase P, test sample) −
(average Ct of target gene, reference samples − average Ct
of RNase P, reference samples) and then using the formula
2 × 2− ΔΔCt [20]. The cutoff value of target genes was set
at 3 standard deviation of the mean derived from the six
normal control samples. Each sample was then assigned
to have diploidMET CN, gain, or loss.
Statistical analysis
The associations between MET CN and various clinical
and immunophenotypical parameters were assessed by
χ2 test or Fisher’s exact test. Kaplan–Meier survival
curves were drawn and the log rank test was used to
compare the differences between survival curves. All
statistical analyses were performed using SPSS for win-
dows 11.0 software (SPSS Inc. Chicago, IL). A P value of
0.05 or less was considered statistically significant.
Results
These 28 patients included 12 males and 16 females with
a median age of 70 years (range, 26 to 88). Six patients
(21%) presented with intestinal perforation. The staging
results were available in 27 patients including 9 (33%) at
stage IE, 14 (52%) at stage IIE and 4 (15%) at stage IVE.
Nineteen patients (70%) received chemotherapy with
cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone (CHOP) or similar regimens. Among these, 12
patients received combined Rituximab therapy and
others additional radiotherapy. Eight patients (30%)
received only supportive treatment without chemo- or
radiotherapy due to poor general condition. The mean
follow-up time was 32 months (range, 0.3 to 110). The
overall 1-, 2- and 5-year survival rates were 50, 43 and
18%, respectively. Immunohistochemically, 22 tumors
(79%) expressed bcl-2, bcl-6 and MUM1/IRF4; while
only 6 tumors (21%) expressed CD10. Nineteen tumors
(68%) had concurrent expression of bcl-2 and MUM1.
All tumors were negative for cyclin D1. Seven tumors
(25%) were classified as germinal centre B-cell (GCB)
phenotype and 21 non-GCB (75%) according to the al-
gorithm of Hans et al. [21]. Patients with intestinal per-
foration at presentation showed a poor prognosis
compared to those without (P = 0.004; Figure 1). The
other clinicopathological or immunohistochemical find-
ings including all differentiation markers and GCB vs.
non-GCB phenotype were of no prognostic significance.
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Table 1 summarizes the associations between MET CN
and the clinicopathologic features. Of these 28 cases the
median MET CN was 2.20 (range, 1.04 to 3.35; Figure 2).
Deriving from the results of normal control specimens,
the tumors with a cut-off value of greater than 2.35 copies
was designated as having MET CN gain, and those with
less than 1.77 as CN loss. According to these criteria, 11
patients (39%) had MET CN gain (median: 2.94 copies;
range, 2.48 to 3.35), 8 (29%) with CN loss (median: 1.33;
range, 1.04 to 1.66), and 9 (32%) with normal/diploid CN
(median: 2.00; range, 1.91 to 2.28). Patients with MET CN
gain or normal/diploid MET CN showed a significant
worse prognosis than those with MET CN loss (P = 0.046;
Figure 3). We also found that the patients with MET CN
gain of greater than 3 copies showed a poorer prognosis
as compared to those with CN of less than 3 (P = 0.003;
Figure 4). There was also a significant correlation between
MET CN gain of greater than 3 copies and perforation at
disease presentation (P = 0.002).
Discussion
In this study, we investigated the prognostic role of the
MET CNAs in surgically resected PI-DLBL and found
that tumors with MET CN gain greater than 3 copies
were associated with an unfavorable prognosis and also
with perforation at disease presentation. Normal or
lower level MET CN gain also denoted a trend toward
poor prognosis, although the statistical significance was
low. We speculate that the clinical impact of MET CN
on prognosis might be amplification dosage dependent.
Figure 1 Cumulative survival shows a significantly poorer outcome in patients presented with perforation.
Table 1 Correlation between MET copy number and
parameters
MET copy number
Case no. (%) >3 copies (%) P Loss (%) P
Gender
Male 12 (43) 2 (40) 0.89 3 (38) 0.72
Female 16 (57) 3 (60) 5 (62)
Age (years)
≥60 8 (29) 1 (20) 0.65 2 (25) 0.8
<60 20 (71) 4 (80) 6 (75)
B symptom
Present 6 (22) 1 (20) 0.9 0 (0) 0.08
Absent 21 (78) 4 (80) 8 (100)
Perforation
Present 6 (21) 3 (60) 0.02 1 (13) 0.48
Absent 22 (79) 2 (40) 7 (87)
Ann Arbor stage
I or II 23 (85) 5 (100) 0.31 7 (87) 0.83
III or IV 4 (15) 0 (0) 1 (13)
Immunophenotype
GCB 7 (25) 1 (20) 0.78 3 (38) 0.34
Non-GCB 21 (75) 4 (80) 5 (62)
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Figure 2 A representative case with MET copy number data analyzed by CopyCaller Software showing increased FAM to VIC ratio,
indicating increased CN. Abbreviations: FAM, 6-carboxy-fluorescine-labeled MET probe; ROX (carboxy-X-rhodamine), internal reference dye used
for normalization of fluorescent signal variations between wells; VIC: 4,7,2-trichloro-7-phenyl-6-carboxyfluorescein-labeled RNase P probe.
Figure 3 Cumulative survival shows a significantly poorer outcome in patients with diploid or gain of MET CN than those with CN loss.
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Furthermore, we re-confirmed our previous findings that
tumor perforation was a poor prognostic factor in PI-
DLBL and that the relative frequency of GCB phenotype
was low in PI-DLBL, although the latter was not signifi-
cantly related to prognosis [19].
HGF/MET pathway could be activated in both benign
and malignant B-cells. Amplification of the MET gene
would result in MET protein over-expression and consti-
tutive kinase activation [22]. MET CNAs have been
investigated in solid cancer such as gastric carcinoma
and NSCLC [8-10]. Depending on the methods for
assessing MET CNAs, MET amplification has been iden-
tified in 4-21% of gastric carcinomas [23,24]. An increase
of MET CN was associated with higher tumor stage at
presentation and poorer survival in patients with gastric
cancer [10,25]. For a subset of lung cancers with
acquired resistance to epidermal growth factor receptor-
targeting therapy, MET amplification is one of the most
frequently involved mechanisms [26]. In NSCLC, MET
gene has been shown to be amplified in 21-24% of
tumors and the impact of MET CN on prognosis is
histological subtype dependent: MET amplification with
a poorer prognosis in patients with adenocarcinoma but
not in those with squamous cell carcinoma [9,27].
Among the various entities of non-Hodgkin lymph-
omas, MET is frequently over-expressed in DLBL
[14,15,17]. Over-expression of HGF/MET signaling acti-
vates downstream molecules that control proliferation,
adhesion and apoptosis. In the literature, however, the
prognostic significance of MET over-expression in DLBL
is controversial. High serum HGF levels and overactive
HGF/MET pathway in DLBL patients have been reported
to be linked with unfavorable outcome in several studies
[14,28,29]. On the other hand, Uddin et al. showed a bet-
ter overall survival at 5 years in DLBL patients with MET
over-expression than those with low MET expression level
(76.2% vs. 57.5%; P = 0.0025) [13]. A study from the Mid-
dle East also showed that MET over-expression carried a
better prognosis in DLBL patients [13]. So far MET gene
CN has not been investigated in malignant lymphoma yet.
To the best of our knowledge, our study is the first report
describing the prognostic significance of MET CNAs in
patients with PI-DLBL. Our results suggested that higher
MET CN, possibly leading to MET over-expression, might
be a poor prognostic indicator for PI-DLBL.
High serum HGF levels have been found in patients
with DLBL and MM, and they were associated with an
unfavorable prognosis [14,30-32]. Furthermore, tumor
cells could up-regulate HGF production, through para-
crine and/or autocrine mechanisms, by the surrounding
stromal cells or cancer cells themselves [7,33]. With the
recent development of clinical-grade agents targeting the
HGF/MET pathway, inhibition of this pathway is currently
considered a rational and promising strategy for the treat-
ment of patients with B-cell lymphoma and MM [13,34].
Among these agents, Crizotinib (PF-02341066) is an orally
bioavailable, ATP-competitive, small-molecule inhibitor of
c-METand anaplastic lymphoma kinase, and is considered
Figure 4 Cumulative survival shows a significantly poorer outcome in patients with MET CN > 3 copies than those with CN < 3 copies.
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a very potential agent for treatment of cancers dependent
on these oncogenic kinases for growth and survival
[35,36]. Our results of high MET CN gain in PI-DLBL
patients with poor prognosis suggested that blocking
HGF/MET pathway might be a promising adjuvant thera-
peutic option.
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